Alexion Pharmaceuticals Profile

USD 4.07  3.21%

Acquisition by Leonard Bell of 22500 shares of Alexion Pharmaceuticals subject to Rule 16b-3

Alexion Pharmaceuticals Inc insider trading alert for grant of options to purchase common stock par value $.0001 by Leonard Bell, Chief Executive Officer, on March 15, 2018. This event was filed by Alexion Pharmaceuticals I with SEC on 2005-09-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Alexion Pharmaceuticals Summary

Alexion Pharmaceuticals Inc (ALXN) is traded on NASDAQ in USA. It is located in CONNECTICUT, U.S.A and employs 2,525 people. Alexion Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 26.84 B. Alexion Pharmaceuticals Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 221.68 M outstanding shares of which 4.79 M shares are presently shorted by private and institutional investors with about 1.91 trading days to cover. ALEXION PHARM INC currently holds about 1.48 B in cash with 879.16 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.69.
Check Alexion Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Alexion Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Alexion Pharmaceuticals Against Markets

Current Ratings

Alexion Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 14% 
Equity ratings for Alexion Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company was founded in 1992 and is headquartered in New Haven, Connecticut. Alexion Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 2525 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameAlexion Pharmaceuticals Inc
CEO, DirectorLudwig HantsonView All
Thematic ClassificationBiotechView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
Business Address100 College Street
Foreign Associate  Austria
CIK Number00899866.0
Contact Number475 230 2596
CurrencyUSD - US Dollar


Alexion Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
Alexion Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Alexion Pharmaceuticals Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Alexion Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate1.09April 27, 2017
Alexion Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Alexion Pharmaceuticals Corporate Directors
Felix Baker Director, Ph.D
Andreas Rummelt Independent Director, Ph.D
Deborah Dunsire Independent Director